Inflammatory Bowel Disease (IBD) – Page 3

Dr. Charles McDaniel Joins Texas Digestive Disease Consultants

Dr. Charles McDaniel, a board-certified physician who treats all gastrointestinal disorders while specializing in Barrett’s esophagus, liver disease, hepatology and Inflammatory Bowel Disease (IBD), is joining Texas Digestive Disease Consultants in Sunnyvale, Texas.

“I chose gastroenterology because I enjoy forming relationships with my patients and seeing their progress,” says Dr. McDaniel. “I am open-minded and respect all patient perspectives and preferences; I focus on education revolving around the diagnostic and disease process to discover the very best treatment options.”

Episode #61: SonarMD Reduces ER Visits for IBD Patients (and how GI practices should be thinking about value-based care)

Podcast: Play in new window | Download | Embed

Kevin Harlen interviews Dr. Larry Kosinski, chief medical officer for SonarMD, a remote monitoring and care coordination program for chronic conditions.

Crohn’s and Colitis Foundation Appoints Dr. Douglas Wolf to National Board of Trustees

Dr. Douglas Wolf, a United Digestive physician and Medical Director for the Center for Crohn’s Disease & Ulcerative Colitis, has joined the National Board of Trustees of the Crohn’s and Colitis Foundation, which focuses on IBD research and patient support.

Dr. Wolf has spent more than four decades dedicated to advancing the understanding and treatment of IBD through clinical practice, research, and patient advocacy. His extensive clinical research covers various aspects of IBD, including diagnostic testing, colonoscopy, capsule endoscopy, and therapy.

Episode #48: New Biosimilars Available to Treat IBD (what it means for your patients)

Podcast: Play in new window | Download | Embed

This summer, four new biosimilar drugs became available to U.S. patients and several more are expected to hit the market soon.

Dr. Michael Weinstein interviews Laura D. Wingate, executive vice president, education, support, & advocacy for the Crohn’s & Colitis Foundation about the positive and negative implications of this development for patients.